We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 259383 for:    ALL
Previous Study | Return to List | Next Study

Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion (PRE-ELECTRIC)

This study is currently recruiting participants.
Verified November 2017 by Vestre Viken Hospital Trust
Sponsor:
ClinicalTrials.gov Identifier:
NCT03346863
First Posted: November 17, 2017
Last Update Posted: November 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Oslo University Hospital
Lund University
Information provided by (Responsible Party):
Vestre Viken Hospital Trust
November 14, 2017
November 17, 2017
November 17, 2017
November 2017
December 2021   (Final data collection date for primary outcome measure)
Atrial fibrillation recurrence [ Time Frame: 30 days after electrical cardioversion ]
ECG-documented atrial fibrillation recurrence after successful cardioversion
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion
Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion

In patients with persistent atrial fibrillation (AF), electrical cardioversion is very effective in restoring sinus rhythm if modern, biphasic cardioverters are used. However, approximately 50 per cent of the successfully cardioverted patients experience a recurrence of AF within a few weeks. Therefore, valid predictors for AF recurrence would be of great clinical relevance, to avoid unnecessary procedures.

In the PRE-ELECTRIC study, we will investigate the predictive value of potential new biomarkers with respect to AF recurrence within 30 days after electrical cardioversion. We will investigate serum and plasma biomarkers, electrocardiological markers and echocardiographic variables in this respect. The study will be undertaken as a prospective cohort study at Bærum Hospital, Vestre Viken Hospital Trust, with national and international collaborators.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Serum, EDTA Plasma, Citrated Plasma, EDTA Whole Blood
Non-Probability Sample
Patients > 18 years referred for electrical cardioversion for ECG-documented persistent atrial fibrillation.
Atrial Fibrillation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
270
December 2022
December 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients > 18 years referred for electrical cardioversion for persistent atrial fibrillation
  • Signed, informed consent

Exclusion Criteria:

  • Patients < 18 years
  • Patients with paroxysmal atrial fibrillation
  • Patients unwilling to participate or without consent competence
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Arnljot Tveit, MD, PhD 0047-97171773 arnljot.tveit@vestreviken.no
Contact: Mona Olufsen, RN 0047-90637441 mona.olufsen@vestreviken.no
Norway
 
 
NCT03346863
PRE-ELECTRIC 2017/1604
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Vestre Viken Hospital Trust
Vestre Viken Hospital Trust
  • Oslo University Hospital
  • Lund University
Not Provided
Vestre Viken Hospital Trust
November 2017